SGX Market Updates

Highlights of SGX’s Largest, Best-Performing Healthcare Services Stocks


PUBLISHED ON |

31 January 2019

  • The performance of Singapore’s listed healthcare sector is measured by the iEdge SG All Healthcare Index. In the YTD, the iEdge SG All Healthcare Index has generated a total return of 7.6% vs the benchmark STI's total return of 3.9%.

  • In the YTD, the 5 largest and best-performing healthcare services stocks were: ISEC Healthcare (+7.8%), Singapore Medical Group (+3.8%), OUE Lippo (+3.1%), Thomson Medical (+2.7%), and IHH Healthcare (+1.7%). They averaged a total return of +3.8% over the period.

  • The majority of Singapore’s healthcare service providers have pursued international expansion plans in recent years, with operations and assets spanning multiple geographies outside Singapore. Investors can participate in the structural Asian healthcare theme through these companies.




There are 18 healthcare service providers listed on SGX that operate patient care services and facilities in Singapore and worldwide. These facilities include laboratories, hospitals, nursing homes and clinics that offer services and treatments ranging from family medicine, dentistry, endoscopy and aesthetics to gynaecology, oncology, paediatrics, orthopaedics, ophthalmology and even cord blood banking.

Some of the healthcare services companies that have listed on SGX in the last two years include Medinex Ltd (December 2018), Asian Healthcare Specialists (April 2018), Clearbridge Health (December 2017), and Aoxin Q & M Dental (April 2017).

The performance of Singapore’s listed healthcare sector is measured by the iEdge SG All Healthcare Index, which is a free-float, market capitalisation-weighted index comprising 31 stocks. Healthcare service providers are well-represented, accounting for more than half the Index’s constituents.

In the 2019 year-to-date, the iEdge SG All Healthcare Index has generated a total return of 7.6%. This compares with total returns of 3.9% for the benchmark Straits Times Index (STI) over the same period.

2019 YTD Total Returns Of Healthcare Index vs STI



Five Largest Best Performers in YTD

In the YTD, the 5 largest (market capitalisation above S$100 million) and best-performing healthcare services companies on SGX have averaged a total return of +3.8%. This brings their one-year and three-year total returns to -27.8% and +23.1% respectively.

They were: ISEC Healthcare (+7.8%), Singapore Medical Group (+3.8%), OUE Lippo Healthcare (+3.1%), Thomson Medical Group (+2.7%), and IHH Healthcare (+1.7%). These 5 plays have a combined market value of nearly S$20 billion, largely due to secondary-listed heavyweight IHH Healthcare.

Over the same period, the 5 largest, least-performing healthcare service providers were: Healthway Medical Corp (-6.3%), Talkmed Group (-5.8%), Singapore O&G (-2.9%), Q&M Dental Group (-1.0%), and Raffles Medical Group (+0.9%).

Name SGX
Code
Market
Cap
(S$ mln)
Total
Return
YTD (%)
Total
Return
1Y (%)
Total
Return
3Y (%)
Div Ind
Yld (%)
ISEC HEALTHCARE 40T 142.1 7.8 -12.4 17.6 5.4
SINGAPORE MEDICAL GRP 5OT 199.2 3.7 -32.0 151.5 NA
OUE LIPPO HEALTHCARE 5WA 293.2 3.1 -46.1 11.0 NA
THOMSON MEDICAL GRP A50 1,981.6 2.7 -40.3 -48.3 NA
IHH HEALTHCARE Q0F 16,047.8 1.7 -8.1 -16.0 0.5
Average 3.8 -27.8 23.1

Source: Bloomberg & StockFacts (data as of 29 January 2019)



Defensive With Robust Prospects

Singapore’s healthcare sector is typically viewed as a defensive segment, poised to enjoy multi-year growth prospects. Drivers of Asia’s increased healthcare spending levels include accelerated ageing rates, the rise of lifestyle diseases like diabetes and hypertension, as well as growing disposable incomes. 

Frost & Sullivan has estimated that the Asia- Pacific healthcare industry expanded at 11.1% in 2018, accounting for 28% of the US$2 trillion global market. This represents one of the fastest growing regions in the world, with the global healthcare economy averaging only a 4.8% annual growth rate. The positive expansion is fuelled by increasing adoption of technology, innovative healthcare access programs and delivery of care outside traditional hospital settings.

Between July and December 2018, Singapore’s healthcare sector saw six consecutive months of net inflows by institutional investors, according to SGX data. The sector has benefited from investor interest, following increased risk aversion on the back of higher market volatility and persistent US-China trade tensions. For a recently published Market Update on healthcare sector fund flows, click here.



Wide Geographical Reach

The majority of Singapore’s healthcare service providers have also pursued international expansion plans in recent years. Their operations and assets span multiple geographies outside Singapore, including markets in South and Southeast Asia, Northeast Asia, as well as Middle East and Europe.

In particular, IHH Healthcare has medical centre and/or hospital operations in China, Hong Kong, India, Brunei and Malaysia, while its Europe and Middle East exposure includes Iraq, United Arab Emirates, Turkey, Bulgaria and Macedonia. Likewise, OUE Lippo Healthcare runs hospitals in China as well as nursing and assisted living facilities in Japan, while home-grown Raffles Medical Group has expanded its presence in more than 10 cities across Asia – operating hospitals in Hong Kong and Shanghai, as well as clinics in Vietnam and Cambodia.

Investors can easily participate in the structural Asian healthcare theme through SGX-listed healthcare stocks that are rapidly expanding into regional and global markets to meet growing patient needs.







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












Stock / REIT Search

Advertisement

Advertisement